Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel

  • Daniel W. Yokom Princess Margaret Cancer Centre
  • John Stewart Sanofi Canada
  • Nimira S. Alimohamed Tom Baker Cancer Centre
  • Eric Winquist London Health Sciences Centre
  • Scott Barry Odette Cancer Centre, Sunnybrook Health Sciences Centre
  • Stacey Hubay Grand River Regional Cancer Centre
  • Jean-Baptiste Lattouf Division or Urology, Centre Hospitalier de l’Université de Montréal (CHUM)
  • Helene Leonard Centre Hospitalier de l’Université de Montréal (CHUM), Notre-Dame Hospital
  • Carla Girolametto Grand River Regional Cancer Centre
  • Fred Saad Division or Urology, Centre Hospitalier de l’Université de Montréal (CHUM)
  • Srikala S. Sridhar Princess Margaret Cancer Centre

Abstract

Introduction: Cabazitaxel is one of several treatment options available for patients with metastatic castration-resistant prostate cancer who have progressed on docetaxel. Little is known about clinical factors that influence prognosis or treatment response for patients receiving cabazitaxel. Identifying prognostic and predictive factors could contribute to the optimal selection of patients for treatment after docetaxel.

Methods: A retrospective review of patients enrolled on the cabazitaxel Canadian Early Access Program (C-EAP) was performed. Clinical factors were analyzed by univariable and multivariable Cox proportional hazards and logistic regression analysis to identify independent predictors of prognosis and response.

Results: Forty-five patients from five centres in Canada were included in this study. On multivariable analysis, lower hemoglobin was associated with shorter survival. No other factors were independently associated with survival, prostate-specific antigen (PSA) response, or primary PSA progression.

Conclusions: Clinical factors predicting survival or treatment response were not identified for men with castration-resistant prostate cancer receiving cabazitaxel. Larger studies may be necessary to identify clinical factors and biomarkers that identify whether patients should or should not receive cabazitaxel.

Published
2018-03-26
How to Cite
Yokom, D. W., Stewart, J., Alimohamed, N. S., Winquist, E., Barry, S., Hubay, S., Lattouf, J.-B., Leonard, H., Girolametto, C., Saad, F., & Sridhar, S. S. (2018). Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. Canadian Urological Association Journal, 12(8). https://doi.org/10.5489/cuaj.5108
Section
Original Research